Otros idiomas Hansa Biopharma AB

Acciones

HNSA

SE0002148817

Mercado cerrado - Nasdaq Stockholm Otros sitios de cotización 17:29:56 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
29,74 ^SEK	+4,72 %		+8,86 %	+13,51 %

18/04	Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024
18/04	Hansa Biopharma AB (publ) informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Correction: Hansa Biopharma: increase in number of shares and votes	03/05
Hansa Biopharma: increase in number of shares and votes	03/05
Hansa Biopharma Q1 - Improved European launch support	19/04
Hansa Biopharma interim report January-March 2024	18/04
Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	18/04
Hansa Biopharma Approves SEK372 Million Directed Share Issue	12/04
Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)	12/04
Hansa Biopharma AB Provides Preliminary Unaudited Revenue Guidance for the First Quarter Ending March 31, 2024	02/04
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance	02/04
Hansa Biopharma publishes 2023 Annual and Sustainability Reports	21/03
Hansa Biopharma Hires New CFO	22/02
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer	22/02
Hansa Biopharma AB Announces CFO Changes	22/02
Hansa Biopharma - Improved sales prospects	05/02
Hansa Biopharma Year-end report January-December 2023	02/02
Hansa Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02/02
Hansa Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	02/02
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference	06/01
Hansa Biopharma and Newbridge Pharmaceuticals Forms Partnership to Enable Supply of Novel Treatment Idefirix to Kidney Transplant Patients in the Middle East and North Africa	06/01
Hansa Biopharma AB Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	06/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Hansa Biopharma AB

Acciones

HNSA

SE0002148817

Otros idiomas

Filtros